{
  "docId": "019de077-0326-7579-845c-ff13347b3147",
  "docSlug": "a6759fd47798a8f3f6e744ad8917865e",
  "documentTitle": "Exscientia | Investor Presentation Deck | 93 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 49,
  "pageCount": 93,
  "prevPage": 48,
  "nextPage": 50,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a human anatomy diagram to map specific cancer types to their locations, providing a visual representation of the addressable market.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0326-7579-845c-ff13347b3147/49",
  "deckHref": "/decks/019de077-0326-7579-845c-ff13347b3147",
  "deckJsonHref": "/decks/019de077-0326-7579-845c-ff13347b3147.json",
  "deckAnchorHref": "/decks/019de077-0326-7579-845c-ff13347b3147#slide-49",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.07,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "Covers all indications included in Ph1/2 ELUCIDATE trial; Patient counts for each subtype based on EvaluatePharma Epidemiology 2022 and primary inclusion criteria for ELUCIDATE Ph 1/2 trial. Treatment rate and progression rates based on Cerner Enviza Treatment Architecture Reports 2022; Numbers have been rounded to the nearest 1000 patients per year; *Excludes currently actionable driver mutations such as ALK, EGFR, BRAF, ROS1, RET and MET",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5b3b004-7e34-4b0c-910f-36f96b661a53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.895,
        "w": 0.235,
        "x": 0.228,
        "y": 0.198
      },
      "kind": "image",
      "text": "Human anatomy diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd44b332-c9b7-4e81-9b95-1df247c276d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.07,
        "y": 0.23
      },
      "kind": "list",
      "text": "5K Head & Neck Cancer; 29K Non-small Cell Lung Cancer; 6K Ovarian Cancer; 12K Breast Cancer; 8K Pancreatic Cancer; 15K Colorectal Cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09534339-c5ba-40c4-9c36-c2ff58c0dcc3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.68,
        "y": 0.46
      },
      "kind": "metric",
      "text": "~75K U.S. Patients Lives Annually",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a056b4c8-eae2-4304-8cba-970bdfce887f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.07,
        "y": 0.14
      },
      "kind": "title",
      "text": "2022 United States incidence for patient sub-groups included in ELUCIDATE trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a5a0a8c-5293-4720-a34e-39b4373b260a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "ELUCIDATE: '617 Phase 1/2 ongoing in advanced solid tumours",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7281d68-6bac-46ab-973f-19887bd96ae6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-segmentation",
      "slug": null,
      "matchId": "966b96f4-02a6-4b9c-823d-133ece58caa5",
      "evidence": "Breakdown of total addressable patient population by specific cancer sub-types.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 76,
      "from": 40,
      "beatId": "5ac1e19c-a020-4b03-85c5-f8d4af660d2d",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Highlighting of Exscientia's achievements and partnerships",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}